nejm semaglutide ckd ❇️Patients with obesity, type 2 #diabetes and chronic kidney disease are at high risk for kidney failure, cardiovascular events, and death. This study, the FLOW trial now published, evaluated treatment with (# Effects of Semaglutide on Chronic
Description
Eli Lilly stock surged 7% in a single session after Medicare moved to cover weight-loss drugs at $50 a month and a European panel backed its cancer drug
Results The all semaglutide OW cohort included 772 patients, and IPTW adjusted cohorts included 416 semaglutide OW patients and 1093 SGLT2i patients

Advanced Weight Loss & Glycemic Benefits

Learn the differences in safety, regulation, and dosing
